Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
19
|
| pubmed:dateCreated |
1989-7-7
|
| pubmed:abstractText |
Dilevalol combines vasodilation due to selective beta 2 agonism and nonselective beta antagonism. We studied 311 patients randomized to dilevalol and 138 to metoprolol in a multicenter trial. After a 4-week placebo washout, dilevalol was titrated from 200 to 1,600 mg once daily and metoprolol from 100 to 400 mg to a goal supine diastolic blood pressure less than 90 and greater than or equal to 10 mm Hg decrease from baseline. Responders were followed for 1 year. The average age of patients was 51 years; 72% were men and 54% were white. Both drugs reduced blood pressure effectively to a similar level. Fewer patients discontinued dilevalol than did those taking metoprolol (9 vs 16%; p less than 0.03). More metoprolol-treated patients withdrew because of depression (6 vs less than 1%; p = 0.03) and impotence (5 vs less than 1%; p = 0.03). Lipoprotein levels before and after treatment were measured in 99 patients treated for 53.5 weeks with dilevalol (mean dose 438 mg). Dilevalol increased high-density lipoprotein (HDL) cholesterol by 2.5 mg/dl to 47.2 (p = 0.05), reduced low-density lipoprotein (LDL) cholesterol by 2.5 mg/dl, increased HDL/LDL by 0.03, and decreased total cholesterol/HDL cholesterol by 0.18. Triglycerides increased by 21 mg/dl (p = 0.06). In patients with an initial HDL cholesterol less than 35 mg/dl, dilevalol increased it by 9 mg/dl. In patients treated with metoprolol, the only significant change (p = 0.02) was a 41.9-mg/dl increase in triglyceride levels.(ABSTRACT TRUNCATED AT 250 WORDS)
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic beta-Agonists,
http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic beta-Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol,
http://linkedlifedata.com/resource/pubmed/chemical/Hydrochlorothiazide,
http://linkedlifedata.com/resource/pubmed/chemical/Labetalol,
http://linkedlifedata.com/resource/pubmed/chemical/Lipoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Metoprolol,
http://linkedlifedata.com/resource/pubmed/chemical/Triglycerides
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0002-9149
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
5
|
| pubmed:volume |
63
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
58I-63I
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:2567113-Adrenergic beta-Agonists,
pubmed-meshheading:2567113-Adrenergic beta-Antagonists,
pubmed-meshheading:2567113-Aged,
pubmed-meshheading:2567113-Cholesterol,
pubmed-meshheading:2567113-Coronary Disease,
pubmed-meshheading:2567113-Double-Blind Method,
pubmed-meshheading:2567113-Female,
pubmed-meshheading:2567113-Heart Rate,
pubmed-meshheading:2567113-Humans,
pubmed-meshheading:2567113-Hydrochlorothiazide,
pubmed-meshheading:2567113-Hypertension,
pubmed-meshheading:2567113-Labetalol,
pubmed-meshheading:2567113-Lipoproteins,
pubmed-meshheading:2567113-Male,
pubmed-meshheading:2567113-Metoprolol,
pubmed-meshheading:2567113-Middle Aged,
pubmed-meshheading:2567113-Multicenter Studies as Topic,
pubmed-meshheading:2567113-Random Allocation,
pubmed-meshheading:2567113-Risk Factors,
pubmed-meshheading:2567113-Supination,
pubmed-meshheading:2567113-Triglycerides
|
| pubmed:year |
1989
|
| pubmed:articleTitle |
Influence of beta 2 agonism and beta 1 and beta 2 antagonism on adverse effects and plasma lipoproteins: results of a multicenter comparison of dilevalol and metoprolol.
|
| pubmed:affiliation |
University of Miami Medical School, Florida.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Multicenter Study
|